荷兰STRIDER试验:西地那非治疗早发型胎儿生长受限的统计分析计划
本文为荷兰STRIDER随机临床试验的详细统计分析计划,该试验纳入360名严重早发型胎儿生长受限孕妇,比较西地那非25mg每日三次口服与安慰剂对胎儿及新生儿死亡的影响。计划预设了主次要结局、探索性结局和亚组分析,并在180名患者完成研究后进行中期分析,数据安全监察委员会建议提前终止试验。
要点
- 试验纳入360名严重早发型胎儿生长受限孕妇,西地那非25mg每日三次口服对比安慰剂。
- 主要结局为出院时死亡或严重新生儿疾病的复合终点。
- 中期分析后数据安全监察委员会建议提前终止试验。
核心结论
- 本统计分析计划在不知晓揭盲数据的情况下预先制定,并在中期分析终止试验后更新。
研究设计与样本
- 荷兰10家三级医院和1家二级医院开展的多中心随机临床试验,计划纳入360名严重早发型胎儿生长受限孕妇。
主要发现
- 中期分析在180名患者完成研究后进行,数据安全监察委员会建议提前终止试验。
- 最终分析将由两名统计合格人员独立按照本计划进行。
关键数值与推荐
- 主要结局为出院时评估的死亡或严重新生儿疾病的复合终点。
- 次要结局包括神经发育障碍、Bayley III认知和运动评估平均分、子痫前期或HELLP综合征比例、子宫动脉/脐动脉/大脑中动脉搏动指数、出生体重及分娩或宫内死亡时的孕周。
- 干预为西地那非25 mg或安慰剂口服每日三次。
临床怎么用
- 本统计分析计划旨在减少选择性报告和数据驱动分析的风险,确保试验结果的可靠性。
局限性
- 试验在中期分析后提前终止,可能影响最终分析的统计效能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of the Dutch Sildenafil therapy in dismal prognosis early onset fetal growth restriction (STRIDER) randomised clinical trial is to assess the beneficial and harmful effects of sildenafil versus placebo on fetal and neonatal mortality in pregnant women with severe early-onset fetal growth restriction. The objective of this detailed statistical analysis plan is to minimize the risks of selective reporting and data-driven analysis. SETTING: The setting is 10 tertiary care hospitals and one secondary care hospital in The Netherlands. PARTICIPANTS: The participants will be 360 pregnant women with severe early-onset fetal growth restriction. INTERVENTIONS: The intervention is sildenafil 25 mg or placebo orally three times a day. PRIMARY AND SECONDARY OUTCOME MEASURES: The primary outcome is a composite of death or major neonatal morbidity assessed at hospital discharge. The secondary outcomes are neurodevelopmental impairment; mean scores of the Bayley III cognitive and motor assessment; the proportion of patients experiencing either preeclampsia or haemolysis, elevated liver enzymes, and low platelets syndrome; pulsatility index of uterine arteries, umbilical artery, and middle cerebral artery; birthweight; and gestational age at either delivery or intra-uterine death. RESULTS: A detailed statistical analysis is presented, including pre-defined exploratory outcomes and planned subgroup analyses. One interim analysis after 180 patients had completed the study was planned and a strategy to minimise the risks of type I errors due to repetitive testing is presented. During review of this manuscript the interim analysis was performed by the Data Safety Monitoring Board and early stopping of the trial was recommended. Final analyses will be conducted independently by two statistically qualified persons following the present plan. CONCLUSION: This pre-specified statistical analysis plan was written and submitted without knowledge of the unblinded data and updated after stopping of the trial at interim analysis. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02277132 . Registered on 29 September 2014. Original protocol for the study: doi: https://doi.org/10.5281/zenodo.56148.
引用
- Pels A, Jakobsen JC, Ganzevoort W, et al. Detailed statistical analysis plan for the Dutch STRIDER (Sildenafil TheRapy In Dismal prognosis Early-onset fetal growth Restriction) randomised clinical trial on sildenafil versus placebo for pregnant women with severe early onset fetal growth restriction. Trials. 2019. PMID: 30635020. doi:10.1186/s13063-018-3136-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。